Polaryx Therapeutics (FRA:1V8) Total Assets: €3.03 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1V8 Polaryx Therapeutics Inc FRA:1V8
13 GF Score
Price €1.78
View Full Analysis

What is Polaryx Therapeutics Total Assets?

Polaryx Therapeutics FRA:1V8 -7.88% 13 Total Assets is €3.03 Mil as of Mar. 2026. GuruFocus rates FRA:1V8 with a GF Score™ of 13/100.

Polaryx Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was €3.03 Mil.

During the past 12 months, Polaryx Therapeutics's average Total Assets Growth Rate was -92.90% per year.

Total Assets is connected with ROA %. Polaryx Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -236.54%. Total Assets is also linked to Revenue through Asset Turnover. Polaryx Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Polaryx Therapeutics  (FRA:1V8) Total Assets Explanation

Total Assets is connected with ROA %.

Polaryx Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-8.804/( (4.415+3.029)/ 2 )
=-8.804/3.722
=-236.54 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Polaryx Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (4.415+3.029)/ 2 )
=0/3.722
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Polaryx Therapeutics Total Assets Related Terms

Polaryx Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Polaryx Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Polaryx Therapeutics Total Assets Chart

Polaryx Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Total Assets
2.12 4.78 4.42

Polaryx Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.11 3.07 5.10 4.42 3.03
FRA:1V8
13GF Score
Polaryx Therapeutics Inc FRA:1V8
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Polaryx Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Polaryx Therapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=3.899+0.517
=4.42

Polaryx Therapeutics's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=2.152+0.877
=3.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of €3.03 Mil mean?
Polaryx Therapeutics (FRA:1V8) has a Total Assets of €3.03 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Polaryx Therapeutics and its competitors.
Is Polaryx Therapeutics' Total Assets too high?
Polaryx Therapeutics' current Total Assets is €3.03 Mil. Overall, Polaryx Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Polaryx Therapeutics' Total Assets compare to ?
Polaryx Therapeutics' Total Assets of €3.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Polaryx Therapeutics and its competitors. Polaryx Therapeutics's current Total Assets is €3.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polaryx Therapeutics stock overvalued right now?
Polaryx Therapeutics (FRA:1V8) has a current Total Assets of €3.03 Mil. The current Total Assets is €3.03 Mil. Polaryx Therapeutics' overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Polaryx Therapeutics (FRA:1V8), the current Total Assets is €3.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Polaryx Therapeutics Business Description

Comparable Companies
Other Exchanges PLYX:USA
Address South Tower, 140 East Ridgewood Avenue, Suite 415, Paramus, NJ, USA, 07652
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
13GF Score

Get the complete analysis for FRA:1V8

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.78
Price